An interventional study of GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in Abdominal Aortic Aneurysm, Pararenal Aortic Aneurysm and Thoracoabdominal Aortic Aneurysm, sponsored by W.L.Gore & Associates. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by W.L.Gore & Associates · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Aortic Aneurysm, Thoracoabdominal · United States.
Among the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States, this one is the 4th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 21 with no phase, reaches primary completion later than 5 of the 17 other live ones, and was the 25th registered.
63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.
Browse Aortic Aneurysm, Thoracoabdominal studies →15 of the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States are open now. Recruiting first, the newest first:
Aiatella Oy · Sites in United States, Brazil
Ages 22+ · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Konstantinos Arnaoutakis, MD · Sites in United States
Ages 18+
University of California, Davis · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Aortic Aneurysm, Thoracoabdominal studies recruiting now, 18 (72%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.
Median enrollment 126 across the 24 interventional studies, 235 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 26 have an industry lead sponsor. The 10 most frequent:
W.L.Gore & Associates is the lead sponsor of 96 studies on the registry; 20 are open to participants now.
W.L.Gore & Associates has 5 studies filed under Aortic Aneurysm, Thoracoabdominal — fewer than ten, so there is no comparison to draw.
3 of the studies in Aortic Aneurysm, Thoracoabdominal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526676University of California, Los AngelesClinical Outcomes and Major Adverse Events in Patients Treated With Physician-Modified Fenestrated and Branched Stent Grafts | 2026-12 |
| NCT06578741W.L.Gore & AssociatesGORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study | 2027-06-25 |
| NCT02043691University of Alabama at BirminghamEvaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
A maximum of 300 adult subjects will be enrolled at up to 60 U.S. centers, with a minimum of 70 subjects enrolled at study centers with no prior experience using the TAMBE Device. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 10 years post implant.
63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.
This study's enrollment of 310 is above the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.
Browse Aortic Aneurysm, Thoracoabdominal studies →W.L.Gore & Associates is the lead sponsor of 96 studies on the registry; 20 are open to participants now.
Compared within Aortic Aneurysm, Thoracoabdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Aneurysm, Abdominal. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject is / has:
Exclusion Criteria:
The subject is / has:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Device: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
Co-Primary Endpoint #1: Technical Success
All of the qualifying criteria are met (in the absence of surgical conversion or mortality, type I or type III endoleak, branch occlusion, or graft limb obstruction): * Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits at index procedure. * Successful delivery and deployment of the aortic stent graft and all modular stent graft components at index procedure * Successful side branch catheterization and placement of bridging stents with restoration and maintenance of flow in all intended target vessels at final completion angiography. * Absence of type I or type III endoleaks at final completion angiography. * Patency of all aortic modular stent graft components and intended side branch components at final completion angiography.
Time frame: Time of index procedure
Co-Primary Endpoint #2: Clinical Success
All of the following qualifying criteria are met from the initiation of the index procedure through 12 months post-index procedure: * Technical success * Absence of death from the initial procedure, secondary intervention, or aorta-related cause * Absence of persistent type I or type III endoleak * Absence of lesion enlargement \>5 mm * Absence of device migration \>10 mm * Absence of failure due to device integrity issues (defined as Grade 2 or 3 in Table 8) * Absence of lesion rupture * Absence of conversion to open surgical repair * Absence of permanent paraplegia (see definition below) * Absence of disabling stroke (see definition below) * Absence of "loss of function" or "end-stage renal disease" stage according to the RIFLE Classification following the index procedure
Time frame: Index procedure through 12 months
Target Vessel Technical Success
Successful catheterization and stent placement in all intended target vessels. Note: For this study, technical success will be reported for the overall procedure and specifically for the vessels targeted for treatment with the branch components (this "target vessel technical success" definition).
Time frame: 30 days, 6 months, annually through 10 years
Secondary Clinical Success
Initial clinical success that is interrupted by a treatment failure and is successfully corrected with secondary reintervention (e.g., a patient undergoes a successful treatment of a type I, II, or III endoleak).
Time frame: 30 days, 6 months, annually through 10 years
Assisted Primary Clinical Success
Clinical success that is obtained initially and continuously maintained with additional secondary reinterventions thus no interruption to initial clinical success.
Time frame: 30 days, 6 months, annually through 10 years
Thirty-Day Mortality
Any death that occurs during the procedure, within the index procedure hospital stay, or within the first 30 days post-index procedure.
Time frame: 30 days
Lesion-Related Mortality
Any death that occurs within the first 30 days, or any death that results from lesion rupture, aorta-related complications (e.g., infection, occlusion, dissection, hematoma), or a complication of a secondary intervention.
Time frame: 30 days, 6 months, annually through 10 years
Major Adverse Events (MAEs)
Includes any of the following: * All-cause mortality; * Myocardial infarction resulting in severe hemodynamic dysfunction necessitating resuscitation, cardiac arrest, or fatal outcome; * Respiratory failure requiring prolonged (\>24 hours from anticipated) mechanical ventilation or reintubation; * Renal function decline characterized by one or more of the following: * \>50% reduction in baseline Estimated Glomerular Filtration Rate (eGFR); or, * New-onset dialysis; * Bowel ischemia requiring surgical resection or not resolving with medical therapy; * Permanent paraplegia (see "permanent paraplegia" definition below) * Any major stroke
Time frame: 30 days, 6 months, annually through 10 years
Secondary interventions
Any Reintervention: Any repeated vascular or nonvascular procedure on the index device (TAMBE Device or any stent or stent graft in contact with any TAMBE component). • Note: Reintervention will be classified as "major", "minor", or "nonvascular" based on the definitions below. Major Reintervention: Deployment of proximal or distal extensions, removal of the device, use of thrombectomy or thrombolysis, and any major open surgical procedure. Minor Reintervention: Endovascular procedures (percutaneous transluminal angioplasty, atherectomy, stenting) without thrombectomy or thrombolysis, interventions to treat branch vessel stenosis, interventions to treat type II endoleaks or branch-related endoleaks, and minor surgical revisions (patch angioplasty) of the access vessels. Nonvascular Reinterventions: Any reinterventions that would not be considered "major reintervention" or "minor reintervention" based on the above definitions.
Time frame: Time of index procedure
Intraprocedural Complications
Any vessel perforation, dissection, or occlusion during target vessel cannulation and/or stenting.
Time frame: 30 days, 6 months, annually through 10 years
Kink
Objective documentation of demonstrable angulation (localized angle of less than 90 degrees when measured along the centerline) in any of the stent components or native target vessel
Time frame: 30 days, 6 months, annually through 10 years
Stenosis
Objective documentation of presence of narrowing with demonstrable flow in any of the components
Time frame: 30 days, 6 months, annually through 10 years
Occlusion
Objective documentation of presence of complete stent occlusion with or without minimal flow into a targeted vessel. Note: Occlusions will be stated if they occurred in the aortic component, in a branch component, or in a contralateral leg component used to treat the aortic disease.
Time frame: 30 days, 6 months, annually through 10 years
Target Vessel Instability
Any death or rupture related to side branch complication (e.g., endoleak) or any secondary intervention indicated to treat a branch-related complication, including endoleak, disconnection, kink, stenosis, occlusion, or rupture.
Time frame: 30 days, 6 months, annually through 10 years
Secondary Patency
Endovascular restoration of patency after occlusion of the side branch, stent, or stent graft has already occurred. Note: Conversion to bypass or inability to treat by endovascular means defines loss of secondary patency.
Time frame: 30 days, 6 months, annually through 10 years
Primary Assisted Patency
Endovascular intervention performed to maintain patency in the presence of stenosis before occlusion.
Time frame: 30 days, 6 months, annually through 10 years
Primary Patency
Uninterrupted patency with no occlusion or procedure performed to maintain patency on the stent or native target vessel. Note: Interventions intended to treat endoleak or stent disconnection do not count as loss of primary patency.
Time frame: 30 days, 6 months, annually through 10 years
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aortic Aneurysm, Thoracoabdominal →